Read by QxMD icon Read


Stanley A Cohen, Marina Aloi, Ramalingam Arumugam, Robert Baker, Kevin Bax, Jaroslaw Kierkuś, Sibylle Koletzko, Paolo Lionetti, Tore Persson, Stefan Eklund
OBJECTIVE: These studies evaluated the safety and efficacy of enteric-coated budesonide for the induction and maintenance of remission of mild-to-moderate Crohn's disease (CD) in children. METHODS: The consecutive, multicenter, open-label, non-comparative studies enrolled patients aged 6-17 years. In the induction study, patients with active CD of the ileum and/or ascending colon received budesonide 9 mg or 6 mg once daily for 8 weeks; in the maintenance study, patients in remission received budesonide 6 mg once daily for 12 weeks...
April 19, 2017: Current Medical Research and Opinion
Barbara M Iwańczak, Józef Ryżko, Piotr Jankowski, Małgorzata Sładek, Agata Wasilewska, Mariusz Szczepanik, Edyta Sienkiewicz, Anna Szaflarska-Popławska, Sabina Więcek, Grażyna Czaja-Bulsa, Bartosz Korczowski, Jolanta Maślana, Franciszek Iwańczak, Magdalena Kacperska
BACKGROUND: Registration of infliximab in Poland has increased chances to induce clinical remission and mucosal healing in the severe form of pediatric Crohn's disease. OBJECTIVES: The aim of this retrospective study was to assess the results and safety of infliximab therapy in the severe form of pediatric Crohn's disease. MATERIAL AND METHODS: The study included 153 children with severe form of non-fistulizing Crohn's disease treated with infliximab...
January 2017: Advances in Clinical and Experimental Medicine: Official Organ Wroclaw Medical University
Edyta Szymanska, Maciej Dadalski, Wieslawa Grajkowska, Sylwia Szymanska, Maciej Pronicki, Jaroslaw Kierkus
INTRODUCTION: Deep remission, defined as clinical remission with mucosal healing (MH), with anti-tumor necrosis factor (TNF)-α agents is a new target for therapy in Crohn's disease (CD). Provided that the efficacy of infliximab (IFX) for induction of MH in CD has been demonstrated, there are much less data for adalimumab (ADA), and none concerning MH on histopathological examination. AIM: To assess the impact of biological therapy with ADA on both endoscopic and histopathological MH in paediatric patients with CD...
2017: Przegla̜d Gastroenterologiczny
Ondrej Fabian, Ondrej Hradsky, Kristyna Potuznikova, Alena Kalfusova, Lenka Krskova, Ludmila Hornofova, Josef Zamecnik, Jiri Bronsky
OBJECTIVES: In pediatric Crohn's disease (PCD), the benefit of microscopy in disease activity assessment and prediction of clinical outcome is, due to the focality and transmurality of the inflammation, disputable. We investigated whether histopathological scoring system predicts complications in pediatric CD and correlates with endoscopical and clinical scores. METHODS: We performed a retrospective study on 63 patients. Endoscopy in the time of diagnosis was evaluated using the Simple Endoscopic Score (SES) and histopathology with the Global Histology Activity Score, both in its original version (GHAS) and its modification (modGHAS)...
January 15, 2017: Pathology, Research and Practice
Katrine Carlsen, Christian Jakobsen, Thomas Kallemose, Anders Paerregaard, Lene Buhl Riis, Pia Munkholm, Vibeke Wewer
OBJECTIVES: Our aim was to investigate predictors of Health Related Quality of Life (HRQoL) with respect to changes in disease parameters over time in children with Inflammatory Bowel Disease (IBD). METHODS: This was a prospective longitudinal study examining the association between HRQoL (IMPACT III) and symptom scores (PCDAI, abbrPUCAI), fecal calprotectin (FC) measures and blood analyses (C-reactive protein [CRP], erythrocyte sedimentation-rate [ESR], orosomucoid [ORM], albumin [ALB], hemoglobin [HB] and vitamin-D [VIT-D]) in a cohort of 10-17 years old IBD patients...
February 4, 2017: Journal of Pediatric Gastroenterology and Nutrition
Christine Mrakotsky, Dunn W Augustine, Christopher Watson, James Canavan, Michael Rivkin, Scott Snapper
BACKGROUND: Structural brain changes in gray and white matter have been previously found in adults with Crohn's disease (CD). We have recently shown similar effects for pediatric CD in 2 separate studies (Mrakotsky et al., 2012, 2013, 2015), particularly for cortical and subcortical brain regions important for cognition, memory and emotion. Our prior data also revealed serum markers of inflammation and steroid therapy to be negatively associated with cortical thickness, subcortical volume, cognitive and school function, however, associations between brain structure and more detailed inflammatory profiles have not been studied...
February 2017: Inflammatory Bowel Diseases
David L Suskind, Stanley A Cohen, Mitchell J Brittnacher, Ghassan Wahbeh, Dale Lee, Michele L Shaffer, Kimberly Braly, Hillary S Hayden, Jani Klein, Benjamin Gold, Matthew Giefer, Angela Stallworth, Samuel I Miller
GOAL: To determine the effect of the specific carbohydrate diet (SCD) on active inflammatory bowel disease (IBD). BACKGROUND: IBD is a chronic idiopathic inflammatory intestinal disorder associated with fecal dysbiosis. Diet is a potential therapeutic option for IBD based on the hypothesis that changing the fecal dysbiosis could decrease intestinal inflammation. STUDY: Pediatric patients with mild to moderate IBD defined by pediatric Crohn's disease activity index (PCDAI 10-45) or pediatric ulcerative colitis activity index (PUCAI 10-65) were enrolled into a prospective study of the SCD...
December 27, 2016: Journal of Clinical Gastroenterology
Katarzyna Sznurkowska, Anton Żawrocki, Jacek Sznurkowski, Maciej Zieliński, Piotr Landowski, Katarzyna Plata-Nazar, Ewa Iżycka-Świeszewska, Piotr Trzonkowski, Agnieszka Szlagatys-Sidorkiewicz, Barbara Kamińska
BACKGROUND/AIMS: To determine the proportion of T-regulatory cells (CD4(+)CD25(high)FOXP3(+) cells) in peripheral blood and the number of FOXP3(+) cells in intestinal mucosa of children with inflammatory bowel disease (IBD), and to verify whether these parameters correlate with the activity of the disease. MATERIAL AND METHODS: 24 patients newly diagnosed for IBD were included in the study: ulcerative colitis (UC; n = 13) and Crohn's disease (CD; n = 11). Seventeen healthy controls (HC) and 16 patients with irritable bowel syndrome (IBS) served as a control group for peripheral and intestinal Tregs assessment, respectively...
October 19, 2016: Immunological Investigations
Edyta Szymanska, Maciej Dadalski, Sylwia Szymanska, Wieslawa Grajkowska, Maciej Pronicki, Jaroslaw Kierkus
INTRODUCTION: The clinical efficacy of infliximab (IFX) for induction of remission in both adults and children with active Crohn's disease (CD) has been well documented. Recently, so-called "deep remission" defined as mucosal healing has become the ultimate endpoint of the most recent therapeutic advances for CD. However, endoscopic evidence of mucosal healing is not necessarily associated with histological evidence of suppression of inflammation. AIM: Since data on that issue are limited, especially in the paediatric population, the aim of this study was to assess the impact of induction therapy with IFX on deep microscopic remission in paediatric patients with CD...
2016: Przegla̜d Gastroenterologiczny
Tamir Miloh, Mitchell Shub, Ramon Montes, Kristy Ingebo, Gary Silber, Brad Pasternak
Successful treatment of patients with inflammatory bowel disease (IBD) requires regular intake of medication. Non- adherence to treatment is associated with increased frequency of relapses, morbidity and cost. METHODS: Pediatric IBD patients taking oral medication and with access to text message (TM) services were included. Children were randomized by age, gender, medication administration responsibility (self vs parent) and disease activity (Pediatric Crohn Disease Activity Index (PCDAI) or Pediatric Ulcerative Colitis Activity Index (PUCAI)) into TM intervention and standard of care...
September 6, 2016: Journal of Pediatric Gastroenterology and Nutrition
Sara Valério de Azevedo, Catarina Maltez, Ana Isabel Lopes
BACKGROUND AND AIMS: Increasing evidence in adults demonstrates efficacy and safety of IV iron in inflammatory Bowel disease (IBD) associated iron deficiency anemia; however, evidence in pediatric patients is yet scarce and no previous study has included a long follow-up. This study aimed to evaluate safety and efficacy of IV iron (primary end point), and the need of re-treatment (secondary end point), in this setting. METHODS: Prospective recruitment (40 months); PCDAI determined before and after treatment; anemia defined according to WHO criteria; IV iron treatment included iron sucrose and ferric carboxymaltose...
January 2017: Scandinavian Journal of Gastroenterology
Oriane Truffinet, Christine Martinez-Vinson, Emilie Guerriero, Jean-Pierre Hugot, Jérôme Viala
OBJECTIVES: Tacrolimus is an immunosuppressive agent that has been proposed in the treatment of severe ulcerative colitis. This study examined the effectiveness and safety of tacrolimus in treating refractory Crohn Disease (CD) colitis in children. METHODS: All children treated by oral tacrolimus for CD colitis at a tertiary pediatric center were included in the study. All patients were refractory to steroids and infliximab. Clinical response (decreased PCDAI >15 and PCDAI < 30) and remission (PCDAI <10) were monitored at 2, 4, 6, 12 and 24 months after induction...
July 16, 2016: Journal of Pediatric Gastroenterology and Nutrition
Fabio Pomerri, Faise Al Bunni, Monica Zuliani, Graziella Guariso, Marco Gasparetto, Benedetta Giorgi, Mara Cananzi, Pier Carlo Muzzio
OBJECTIVES: This study was aimed at correlating a magnetic resonance index of activity (MaRIA) and a magnetic resonance enterography global score (MEGS) with activity indexes in a paediatric population with Crohn's disease (CD). METHODS: This retrospective study included 32 paediatric patients (median age 14.5 years, 18 male) with proven CD who underwent magnetic resonance enterography (MRE). A correlation analysis was performed on the MRE-based scores, the simplified endoscopic score for CD (SES-CD), the paediatric Crohn's disease activity index (PCDAI), and C-reactive protein (CRP) levels...
March 2017: European Radiology
K Diederen, D R Hoekman, T Z Hummel, T G de Meij, B G P Koot, M M Tabbers, A M Vlieger, A Kindermann, M A Benninga
BACKGROUND: A large proportion (25-46%) of adults with inflammatory bowel disease in remission has symptoms of irritable bowel syndrome (IBS), which are thought to reflect ongoing inflammation. Data on paediatric inflammatory bowel disease patients are lacking. AIM: To investigate (i) the prevalence of IBS-type symptoms in paediatric inflammatory bowel disease patients in remission and (ii) the relationship of IBS-type symptoms with biochemical markers of disease activity...
July 2016: Alimentary Pharmacology & Therapeutics
Dan Turner, Arie Levine, Thomas D Walters, Gili Focht, Anthony Otley, Victor Navas López, Sibylle Koletzko, Robert Baldassano, David Mack, Jeffrey Hyams, Anne M Griffiths
INTRODUCTION: There is increasing interest in measuring mucosal inflammation in Crohn disease (CD), but there are minimal data correlating the Pediatric Crohn's Disease Activity Index (PCDAI) versions (PCDAI, weighted Pediatric Crohn's Disease Activity Index [wPCDAI], abbreviated Pediatric Crohn's Disease Activity Index [abbrPCDAI], and the short Pediatric Crohn's Disease Activity Index [shPCDAI]) with mucosal inflammation. METHODS: We aimed to compare the 4 PCDAI versions head to head with endoscopic degree of inflammation as measured by the Simple Endoscopic Score for Crohn's Disease (SES-CD), fecal calprotectin, erythrocyte sedimentation rate (ESR), and C-reactive protein (CRP) and to explore cut-off values that are associated with mucosal healing...
February 2017: Journal of Pediatric Gastroenterology and Nutrition
Z Grover, C Burgess, R Muir, C Reilly, P J Lewindon
BACKGROUND: Exclusive Enteral Nutrition (EEN) induction in children with luminal Crohn's disease (CD) gives early mucosal healing (MH), but the long-term benefits of EEN-induced MH are just emerging. AIMS & METHODS: We prospectively followed an Australian cohort of newly diagnosed children with predominantly luminal CD who completed at least six weeks EEN and with paired clinical Pediatric Crohn's Disease Activity Index (PCDAI), biochemical (C-reactive protein; CRP) and endoscopic assessment at diagnosis and post EEN...
October 2016: Journal of Crohn's & Colitis
Amy Grant, Michael Kappelman, Christopher Martin, Anthony Otley
BACKGROUND: The IMPACT-III is a validated, disease-specific HRQOL questionnaire for IBD patients ages 9 to 17. Items within IMPACT are grouped by domains, which cover different aspects of HRQOL. The domain structure has not been changed since validation, although 2 alternate domain structures have been proposed using different methodologies. Using a large, diverse cohort, the aim of this study was to develop the optimal domain structure for IMPACT. METHODS: Three prospectively collected datasets of adolescents with IBD were used: (1) an internet-based cohort of children with IBD from the Crohn's and Colitis Foundation of America (CCFA) Partners Kids & Teens study, (2) the REACH infliximab trial for pediatric Crohn's Disease (CD), and (3) the T72 infliximab trial in pediatric Ulcerative Colitis (UC)...
March 2016: Inflammatory Bowel Diseases
Anne Levine, David Keljo, David DeMaso, Athos Bousvaros, Eva Szigethy
BACKGROUND: Youth with inflammatory bowel disease (IBD) are at increased risk of developing depression. Clinical depression is a heterogeneous disorder comprising different symptom clusters, which may derive from different psychopathologic etiologies. Previous studies identified distinct depressive subtypes among youth with IBD, with nearly 20% experiencing somatic-symptom predominant depression. We aimed to identify depressive symptoms related to inflammatory disease activity in a large sample of youth with Crohn's disease (CD), the subtype of IBD associated with more systemic inflammation...
March 2016: Inflammatory Bowel Diseases
Massimo Martinelli, Caterina Strisciuglio, Annalisa Alessandrella, Francesca Rossi, Renata Auricchio, Natascia Campostrini, Domenico Girelli, Bruno Nobili, Annamaria Staiano, Silverio Perrotta, Erasmo Miele
BACKGROUND AND AIMS: We sought to correlate hepcidin levels in inflammatory bowel disease [IBD] children with disease activity, inflammatory markers, and iron load test [ILT] and to compare IBD patients with coeliac and healthy patients. METHODS: Between December 2012 and June 2013, 145 subjects [50 IBD patients, 45 coeliac patients and 50 healthy controls] were included in the study. All patients underwent the following examinations: blood count, iron status, erythropoiesis parameters, serum hepcidin, C-reactive protein [CRP], and erythrocyte sedimentation rate [ESR]...
May 2016: Journal of Crohn's & Colitis
Jernej Dolinšek, Petra Rižnik, Larisa Sabath, Dušanka Mičetić-Turk
OBJECTIVES: Inflammatory bowel disease (IBD) in children has a remitting and relapsing course. The aim of our study was to evaluate the value of fecal calprotectin (FC), C-reactive protein (CRP), and clinical scores in predicting endoscopic and histological lesions in children with IBD. METHODS: A total of 68 children with IBD (29 with ulcerative colitis (UC), 39 with Crohn's disease (CD), mean age 14.2 years) were included in the study. We retrospectively reviewed clinical scores (PUCAI, PCDAI), CRP values, endoscopic, and histological data as well as FC values in all included children...
April 2016: Wiener Klinische Wochenschrift
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"